These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 26121111)

  • 21. Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis.
    Huang R; Tu S; Deng L; Kang Q; Song C; Li Y
    Hematology; 2015 Jul; 20(6):313-9. PubMed ID: 25321657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation.
    Devillier R; Labopin M; Chevallier P; Ledoux MP; Socié G; Huynh A; Bourhis JH; Cahn JY; Roth-Guepin G; Mufti G; Desmier D; Michallet M; Fegueux N; Ciceri F; Baron F; Blaise D; Nagler A; Mohty M
    Bone Marrow Transplant; 2018 Apr; 53(4):431-437. PubMed ID: 29330391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of patients with hematological malignancies who undergo unrelated donor hematopoietic stem cell transplantation with ATG-Fresenius versus ATG-Genzyme.
    Wang L; Kong P; Zhang C; Gao L; Zhu L; Liu J; Gao S; Chen T; Liu H; Yao H; Liu Y; Feng Y; Zhao L; Li Y; Gao L; Zhang X
    Ann Hematol; 2023 Jun; 102(6):1569-1579. PubMed ID: 37097455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Oncol; 2016 Feb; 17(2):164-173. PubMed ID: 26723083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.
    Zhang W; Gui R; Zu Y; Zhang B; Li Z; Zhang Y; Wang X; Guo S; Zhan X; Fu Y; Song Y; Zhou J
    Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose anti-thymocyte globulin reduce severe acute and chronic graft-versus-host disease after allogeneic stem cell transplantation.
    Imataki O; Matsumoto K; Uemura M
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):709-715. PubMed ID: 28062916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
    Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
    Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
    Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis.
    Admiraal R; van Kesteren C; Jol-van der Zijde CM; Lankester AC; Bierings MB; Egberts TC; van Tol MJ; Knibbe CA; Bredius RG; Boelens JJ
    Lancet Haematol; 2015 May; 2(5):e194-203. PubMed ID: 26688094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
    Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation.
    Nachbaur D; Eibl B; Kropshofer G; Meister B; Mitterschiffthaler A; Schennach H; Fischer G; Kopp M; Gunsilius E; Gastl G
    J Hematother Stem Cell Res; 2002 Aug; 11(4):731-7. PubMed ID: 12201962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.
    Zhang Y; Liu L; Si Y; Miao M; Qiu H; Tang X; Han Y; Fu C; Jin Z; Chen S; Sun A; Wu D
    Hematology; 2021 Dec; 26(1):741-750. PubMed ID: 34555301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Study in Japan.
    Ikegame K; Yoshida T; Yoshihara S; Daimon T; Shimizu H; Maeda Y; Ueda Y; Kaida K; Ishii S; Taniguchi K; Okada M; Tamaki H; Okumura H; Kaya H; Kurokawa T; Kodera Y; Taniguchi S; Kanda Y; Ogawa H
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1495-505. PubMed ID: 25921715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
    Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
    Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
    Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors.
    Vigouroux S; Tabrizi R; Melot C; Coiffard J; Lafarge X; Marit G; Bouabdallah K; Pigneux A; Leguay T; Dilhuydy MS; Schmitt A; Boiron JM; Milpied N
    Biol Blood Marrow Transplant; 2011 Jan; 17(1):93-100. PubMed ID: 20601038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
    Issa H; Sharma N; Zhao Q; Ruppert AS; Elder P; Benson DM; Penza S; Vasu S; William B; Jaglowski S; Devine SM; Efebera YA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1993-2001. PubMed ID: 31229641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients.
    Portier DA; Sabo RT; Roberts CH; Fletcher DS; Meier J; Clark WB; Neale MC; Manjili MH; McCarty JM; Chung HM; Toor AA
    Bone Marrow Transplant; 2012 Dec; 47(12):1513-9. PubMed ID: 22580767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.